Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 18/20 | 0.71 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | CTRL | P40313 | 1/20 | 0.52 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039825 | 0.95 | F2 (0.76) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL18039888 | 0.93 | F2 (0.73) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL18039857 | 0.92 | F2 (0.71) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL18039822 | 0.87 | F2 (0.77) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL18039863 | 0.87 | F2 (0.72) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL29905517 | 0.87 | F2 (0.79) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL18039837 | 0.86 | F2 (0.73) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL20473945 | 0.86 | F2 (0.73) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL29905344 | 0.86 | F2 (0.72) | F2KLKB1F11CTRB1CTRL | |
| SCHEMBL20473850 | 0.86 | F2 (0.70) | F2KLKB1F11CTRB1CTRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | claimed |
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2020-04-09 | — | — | US | disclosed |
| EP-3261639-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | Verseon Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138532-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109132-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINE1 | F2 30/4885KLKB1 9/4885F11 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.